Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
Juno Therapeutics, Inc. (JUNO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/01/2018 |
GN
| New Research: Key Drivers of Growth for Guess?, Acer Therapeutics, American National Insurance, J P Morgan Chase, Juno Therapeutics, and Allergan — Factors of Influence, Major Initiatives and Sustained Production |
| 12/11/2017 |
BW
| Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma |
| 11/01/2017 |
BW
| Juno Therapeutics Reports Third Quarter 2017 Financial Results |
| 11/01/2017 |
BW
| Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH |
| 10/25/2017 |
BW
| Juno Therapeutics to Report Third Quarter 2017 Financial Results on Wednesday, November 1 |
| 09/18/2017 |
GN
| Stull, Stull & Brody Announces Lawsuit Against Certain Officers and Directors of Juno Therapeutics, Inc. (NASDAQ: JUNO) |
| 08/31/2017 |
BW
| Juno Therapeutics to Present at September 2017 Investor Conferences |
| 08/09/2017 |
GN
| Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment |
| 08/03/2017 |
BW
| Juno Therapeutics Reports Second Quarter 2017 Financial Results |
| 07/27/2017 |
BW
| Juno Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3 |
| 05/04/2017 |
BW
| Juno Therapeutics Reports First Quarter 2017 Financial Results |
|
|